- Staff Scientist, Laboratory of Bioorganic Chemistry, NIDDK, NIH, 2004–Present
- General Partner, Universal MS Services, 1991–2004
- Applications Chemist, Finnigan Instruments, 1986–1991
- Senior Scientist, Johnson and Johnson, 1980–1986
- Postdoctoral, Rockefeller University, 1978–1980
- Ph.D., Yale University, 1978
I am involved in the identification of biologically active compounds for the treatment of diseases such as HIV, hepatitis C, tuberculosis, etc.
I conduct advanced mass spectrometric analyses in support of a variety of chemical and biological research disciplines. These analyses include proteomics, natural product identification, quantification of short-chain fatty acids, intact protein identification, and polymer characterization.
Applying our Research
Our work is directed at developing new drug candidates for the treatment of various chronic diseases.
Need for Further Study
The mode of action of new drug candidates needs to be investigated further.
- Say no to DMSO: dimethylsulfoxide inactivates cisplatin, carboplatin, and other platinum complexes.
- Hall MD, Telma KA, Chang KE, Lee TD, Madigan JP, Lloyd JR, Goldlust IS, Hoeschele JD, Gottesman MM.
- Cancer Res (2014 Jul 15) 74:3913-22. Abstract/Full Text
- Meropenem inhibits D,D-carboxypeptidase activity in Mycobacterium tuberculosis.
- Kumar P, Arora K, Lloyd JR, Lee IY, Nair V, Fischer E, Boshoff HI, Barry CE 3rd.
- Mol Microbiol (2012 Oct) 86:367-81. Abstract/Full Text
Research in Plain Language
I use a chemical analysis tool called a mass spectrometer to study samples of various materials. The mass spectrometer analysis shows which chemicals are in a sample. It also shows how much of each chemical is in a sample.